Philip Kuriakose, MD
Internal Medicine · Detroit, MINPI 1366510810
Payments from drug & device makers
Across 322 payments — averaging $5858.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$369K
- Bristol Myers Squibb$236K
- Genentech, Inc.$223K
- Regeneron$134K
- Beigene, Ltd.$117K
- Janssen Research & Development, LLC$91K
- plus $717K from 27 others
Across 4 payments — averaging $3138.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Octapharma USA, Inc.$7K
- AstraZeneca$6K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 19 | $369,168 |
| Bristol Myers Squibb | 18 | $235,835 |
| Genentech, Inc. | 6 | $222,738 |
| Regeneron | 14 | $134,159 |
| Beigene, Ltd. | 12 | $116,650 |
| Janssen Research & Development, LLC | 4 | $91,300 |
| AstraZeneca | 54 | $85,913 |
| E.r. Squibb & Sons, L.L.C. | 10 | $77,218 |
| Morphosys AG | 5 | $74,219 |
| Incyte Corporation | 5 | $72,664 |
| Pfizer | 6 | $56,331 |
| Bayer | 32 | $52,110 |
| AbbVie | 4 | $38,250 |
| F. Hoffmann-la Roche AG | 9 | $31,900 |
| Gilead | 4 | $31,270 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $26,565 |
| Novo Nordisk | 14 | $26,274 |
| Sanofi US Services Inc. | 6 | $26,230 |
| Argenx US, Inc. | 4 | $24,078 |
| Genmab A/s | 33 | $21,452 |
| Shire North American Group Inc | 10 | $18,200 |
| Sanofi | 13 | $17,001 |
| HEMA Biologics, LLC | 9 | $12,520 |
| CSL Behring | 7 | $7,961 |
| Novartis | 1 | $3,200 |
| ADC Therapeutics America, Inc. | 1 | $2,800 |
| Chiesi USA, Inc. | 1 | $2,610 |
| Beone Medicines Ltd. | 1 | $2,346 |
| TG Therapeutics, Inc. | 2 | $2,000 |
| Kedrion Biopharma Inc. | 1 | $1,200 |
| Dova Pharmaceuticals | 1 | $1,150 |
| Bioverativ Therapeutics Inc. | 1 | $750 |
| Morphosys, US Inc. | 1 | $500 |
How this compares
$1,886,562 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Detroit
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Rana BalboulDetroit$2.4M
- Erlene SeymourDetroit$797K
- Sheela TejwaniDetroit$712K
- Vrushali DabakDetroit$509K
- James McCordDetroit$493K
- Saroj NeupaneDetroit$487K
- David StocktonDetroit$402K
- Randall BensonDetroit$396K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.